Isopulegol is a minty monoterpene alcohol best known in aroma chemistry as a lemon-eucalyptus and mint-pathway constituent and as a biosynthetic intermediate related to menthol production. Live identity sources are strong, and the public study literature is broader here than for many aroma constituents, including rodent nociception, seizure, and neuroinflammation models plus regulatory safety reviews for flavor and fragrance use. That said, the efficacy evidence remains preclinical, so AromaForge should frame isopulegol as a well-characterized terpene with promising animal and cell-model findings rather than a validated medical active.
Chemical identity and composition
PubChem resolves isopulegol to the stereochemically defined (-)-isomer with CID 170833, formula C10H18O, and InChIKey ZYTMANIQRDEHIO-KXUCPTDWSA-N. NIST lists CAS 89-79-2 for isopulegol and treats epi-isopulegol, dl-isopulegol, and pulegol as related stereoisomer entries rather than the same record. Within the local archive, isopulegol is a notable secondary constituent in lemon eucalyptus profiles, where it sits below citronellal but above many trace terpenes.
Aroma and practical use
- Use the recorded minty, green, herbal, cooling, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2009 Fitoterapia study found that isopulegol significantly prolonged seizure and mortality latency in PTZ-treated mice, protected all animals from mortality at the higher tested dose, and was partly sensitive to flumazenil pretreatment.
This is the clearest directly attributable anticonvulsant source located in this pass and also links the effect to antioxidant readouts in hippocampal tissue.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2018 Chemico-Biological Interactions paper reported oral antinociceptive effects for isopulegol in formalin, capsaicin, and glutamate mouse models, with pharmacologic antagonism pointing to opioid, muscarinic, KATP, and nitric-oxide/cGMP involvement.
This source supports mechanism-oriented pain-model interest while remaining firmly preclinical.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 Journal of Environmental Pathology, Toxicology and Oncology paper found that isopulegol reversed LPS-associated increases in NO, ROS, and cytokine-related markers in BV-2 cells and improved several abnormalities in an MPTP mouse Parkinson disease model.
This broadens the evidence base beyond seizure and pain models, but it is still cell-and-animal evidence rather than clinical validation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 EFSA FEEDAP opinion concluded that isopulegol is safe at the maximum proposed dose of 5 mg/kg complete feed for all animal species except cats, for which 1 mg/kg was considered safe.
This is one of the stronger regulatory safety anchors available for any AromaForge constituent, though it applies to feed-flavoring exposure rather than wellness use.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe 2020 EFSA FEEDAP assessment concluded that isopulegol was safe at 5 mg/kg complete feed for all animal species except cats, for which the safe level was 1 mg/kg.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A RIFM fragrance safety assessment and its 2022 update are indexed in PubMed, indicating that isopulegol has been reviewed for genotoxicity, repeated-dose toxicity, developmental and reproductive toxicity, local respiratory toxicity, phototoxicity, and sensitization endpoints.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because the strongest benefit-oriented studies are rodent and cell-model papers, archive copy should avoid presenting isopulegol as proven analgesic, anticonvulsant, or neuroprotective therapy in humans.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
possible_gabaa_related_anticonvulsant_action
A PTZ-convulsion mouse study reported that flumazenil pretreatment reduced the seizure-latency benefit from isopulegol, supporting a possible benzodiazepine-sensitive GABA-A component.
This experimental finding does not establish benefit, dose or safety in people using this blend.
opioid_muscarinic_and_no_cgmp_pathway_involvement_in_acute_nociception
A mouse nociception paper found that naloxone, atropine, l-arginine, methylene blue, and glibenclamide attenuated isopulegol's antinociceptive response, suggesting involvement of opioid signaling, muscarinic receptors, KATP channels, and the nitric-oxide/cGMP pathway.
This experimental finding does not establish benefit, dose or safety in people using this blend.
reduction_of_no_ros_and_proinflammatory_mediators_in_microglia_model
In LPS-stimulated BV-2 cells, isopulegol reduced nitric oxide, intracellular ROS, and proinflammatory mediator expression, with accompanying reduction of iNOS and COX-2 signals in the linked MPTP mouse model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical trial specific to isolated isopulegol was verified in this pass.
- The strongest benefit-oriented findings come from rodent and cell models, so translation to human outcomes remains uncertain.
- This record uses the stereochemically defined PubChem and NIST handling for isopulegol, but some commercial sources blur isomer-specific naming.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.